Prevalence of disability improvement in relapsing-remitting multiple sclerosis patients treated with cladribine tablets.

Assessment of the prevalence of EDSS improvement is an alternative outcome to assess if a treatment induces and maintains an improvement over the long term. This estimator was found to be more powerful than the cumulative incidence of improvement to detect a treatment effect of cladribine versus placebo over 5 years.